BUZZ-Valeant Pharmaceuticals Inc: To buy Salix for $10.1 bln
** Canadian drugmaker Valeant's U.S.-listed shares up 7.9 pct at $187 premarket
** Company to buy gastrointestinal drug maker Salix Pharmaceuticals Ltd in all-cash deal valued at about $10.1 bln
** Salix stock down 1 pct at $156.21 premarket, below Valeant's offer price of $158 per share
** Valeant's offer is at significant premium to Salix's intrinsic value of $76.46 per share - Thomson Reuters StarMine data
** Cantor Fitzgerald raises price target on Valeant's stock to $214 from $184; median price target is $183
** Up to Friday's close, Valeant stock had risen 20 pct this year, while NYSE Arca Pharmaceutical Index had risen 6 pct
© Thomson Reuters 2017 All rights reserved.